Kornimate/medical-research-clean huggingface dataset:
protein supplementation in dialysis patients

Conditions: End Stage Renal Disease

Summary: the mortality rate in chronic hemodialysis (chd) patients remains excessively high and approaches 21% per year. among the many factors that adversely affects patient outcome is uremic malnutrition, a unique form of deranged nutritional status. it is associated with increased hospitalization and death risk in chd patients. several measures have been identified to prevent uremic malnutrition in chd patients, including efforts to optimize dialysis regimen and dietary protein and energy intake. a large number of chd patients suffer from uremic malnutrition in spite of these aggressive measures. the inevitable protein catabolic effects of the hemodialysis procedure are important factors leading to increased prevalence of uremic malnutrition. preliminary data suggest that oral nutritional supplementation administered during the hemodialysis procedure counteracts these protein catabolic effects and leads to net protein anabolism in the acute setting. in this proposal, we hypothesize that pro-stat, a high nitrogen, enzyme-hydrolyzed, tryptophan-fortified, collagen protein supplement will reverse the net protein catabolism observed during hemodialysis procedure.


Eligibility criteria:
inclusion criteria: * on hemodialysis for more than 3 months, on a thrice weekly hemodialysis program. * adequately dialyzed (kt/v \> 1.2). * age 18-75 exclusion criteria: * pregnant women. * severe unstable underlying disease besides commonly associated with end stage renal disease. cardiac patients that are stable will be included. * patients hospitalized within the last month prior to the study. * patients with malfunctioning arterial-venous access \[recirculation and/or blood flow \< 500 ml/min for an arterial-venous graft (avg) or \<400 ml/min for an arterial-venous fistula (avf)\] patients receiving steroids and/or other immunosuppressive agents.
the increase study. effect of incremental versus fixed pump on peak oxygen consumption in heart failure patients supported with a continuous flow left venticular assist device

Conditions: Heart Failure.

Summary: the purpose of the study is to examine the relationship between working capacity (peak oxygen consumption) and pump speed of continuous flow left ventricular assist devices (cf-lvads)in heart failure patients. the hypothesis is that it is possible to increase peak oxygen consumption by incrementally increasing cf-lvad pumpspeed during exercise. the study population will consist of severe heart failure patients with cf-lvads treated at the heart centre of copenhagen university hospital rigshospitalet.


Eligibility criteria:
inclusion criteria: * heartmate ii patients who underwent surgery and follow-up at the heart centre of rigshospitalet. * heart failure in stable phase without the need for intravenous inotropic therapy. * ischemic and non-ischemic cardiomyopathy. exclusion criteria: * severe aortic insufficiency.
correlation between premature rupture of membranes and early-onset neonatal infections

Conditions: Premature Rupture of Membrane; Neonatal Infection

Summary: this study hypothesizes that early-onset neonatal infections are related to premature rupture of membrane (prom) and that early intervention can improve the prognosis of newborns. the objective of this study is to analyze the correlation between prom and early-onset neonatal infections and to assess the prognosis of newborns. a cohort study is designed to implement the study. the subjects of study group are pregnant women who are diagnosed as prom or chorioamnionitis and whose gestational age is ≥ 24 weeks. the subjects of control group are pregnant women without prom and chorioamnionitis. control group and research group are paired at 1: 1 ratio. the main contents of the study include three aspects. (1) the correlation between prom and chorioamnionitis. (2) the correlation between prom and early-onset neonatal infections. (3) the pathogenesis of intrauterine infection and neonatal infection.


Eligibility criteria:
inclusion criteria: * prom or chorioamnionitis * gestational age is ≥ 24 weeks exclusion criteria: * gestational age \<24 weeks * artificial rupture of membrane for labor induction * natural rupture of membrane during induction before labor
pentoxifylline and progression of chronic kidney disease in moderate-to-high risk patients

Conditions: Kidney Failure, Chronic

Summary: the purpose of the investigators study is to assess the impact of therapy with pentoxifylline (ptf), a nonspecific phosphodiesterase inhibitor, on kidney function in patients at high-risk for progression to end-stage renal disease. the investigators hypothesize that therapy with pentoxifylline will slow progression of kidney disease over time.

the treatment objective for chronic kidney disease (ckd), regardless of etiology, is to slow or halt progression of renal dysfunction and reduce proteinuria (in those patients with proteinuric renal disease). multi-drug medical regimens remain the cornerstone of therapy for medical-renal disease, often with an angiotensin converting enzyme inhibitor and/or an angiotensin receptor blocker. these therapies, though often efficacious, have not been shown to halt disease progression entirely, and the medical therapy of renal disease remains suboptimal. ptf is a safe, generally well-tolerated drug currently indicated for symptomatic and functional relief of intermittent claudication presumed due to chronic occlusive arterial disease of the limbs. a number of small studies in patients across a range of renal disease states show that ptf can reduce proteinuria, an important component of treatment of ckd. it is not known, however, if the drug will slow progression of ckd as measured by glomerular filtration rate. comparisons: subjects randomized to receive ptf compared with those randomized to receive placebo

Eligibility criteria:
inclusion criteria: patients 18 years of age or older currently being treated with an ace-i or arb and with one of the following conditions: 1. non-nephrotic range proteinuria (between 1 and 3 grams/day by 24-hr collection), hypertension (blood pressure \>130/80 or current use of antihypertensive drug therapy), and an egfr of less than or equal to 40 ml/minute but greater than 20 ml/minute. or 2. nephrotic range proteinuria (\>=3 grams/day proteinuria) by 24-hr urine collection, and an egfr greater than 20 ml/minute exclusion criteria: 1. acute renal failure: defined by \>25% decrease in egfr over one month 2. pregnancy or currently breast-feeding 3. current use of cytotoxic drug therapy (cyclophosphamide, cyclosporine, mycophenolate mofetil, prednisone, chlorambucil) or a current indication for, and plan to implement, such therapy. 4. current use of ptf 5. contraindication to use of ptf drug: history of ptf or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage 6. current use of theophylline 7. contraindication to ace-i or arb. 8. fewer than 2 measured serum creatinine values separated by 6 months prior to potential enrollment

Keywords: proteinuria kidney failure, chronic
psychosocial factors a prognostic study of pain in patients with cmc osteoarthritis

Conditions: Pain; Osteoarthritis

Summary: in this clinical trial, females with a diagnosis of thumb cmc oa, will be recruited. the primary outcome of potential risk factors of osteoarthritis, pain and function will be measured using the demographic data, visual analog scale (vas) and disabilities of the arm, shoulder and hand (quickdash). secondary out-comes will include the pain self-efficacy questionnaire (pseq), tampa scale of kinesiophobia (tsk), fear avoidance beliefs questionnaire (fabq), hospital anxiety and depression scale (hads) and impairment and functioning inventory (ifi). measurements will be taken at the baseline, three, six and 12 months follow up.

the study will start recruitment in april 2019.in this clinical trial, 50-100 females, aged 50 to 90 years of age, with a diagnosis of thumb cmc oa, will be recruited. the primary outcome of potential risk factors of osteoarthritis, pain and function will be measured using the demographic data, visual analog scale (vas) and disabilities of the arm, shoulder and hand (quickdash). secondary out-comes will include the pain self-efficacy questionnaire (pseq), tampa scale of kinesiophobia (tsk), fear avoidance beliefs questionnaire (fabq), hospital anxiety and depression scale (hads) and impairment and functioning inventory (ifi). measurements will be tak-en at the baseline, three, six and 12 months follow up.

Eligibility criteria:
inclusion criteria: * women older than 18 years * diagnosed with bilateral thumb cmc oa * a reported pain intensity during activities of daily living (adls) of up to 4 of 10 on the visual analog scale (vas) * the referring hand surgeon will made the diagnosis of cmc oa based on radiographs and clinical exploration. exclusion criteria: * neurologic disorder affecting the upper limb * had received previous treatment for their hand problem in the last 6 months including an intra-articular joint injection to wrist, fingers, or thumb * had fractures or a significant hand injury or previous surgery to the wrist or hand * had hand or finger tenosynovitis and/or dupuytren disease * patients who did not complete any questionnaire or if they did not sign the informed consent.

Keywords: pain osteoarthritis function
txa in revision total shoulder arthroplasty

Conditions: Arthropathy Shoulder

Summary: this is a phase iv, randomized, single-blind, single-center study comparing calculated total blood loss, surgical drain output and hematoma formation in patients who receive 2 doses of tranexamic acid (txa) versus control group undergoing revision total shoulder arthroplasty. patients will be randomized to either receive 2 doses of iv txa, first dose prior to surgical incision and second dose given 3 hours later or to the control group, where no txa will be administered.

the objectives of the study are to compare the effectiveness of iv txa on reducing calculated total blood loss, surgical drain output and hematoma formation in patients undergoing revision total shoulder arthroplasty.

Eligibility criteria:
inclusion criteria: 1. patients older than 18 years old 2. patients younger than 90 years old 3. patients undergoing scheduled revision total shoulder arthroplasty 4. patients who consent to be randomized exclusion criteria: 1. patients younger than 18 2. patients older than 90 years old 3. patients who are pregnant or breast-feeding women 4. patients who are allergic to tranexamic acid 5. patients with proximal humerus fracture or fracture sequelae 6. patients who use estrogen containing medications (i.e. oral contraceptive pills) 7. patients who have acquired disturbances of color vision 8. patients with a history of any of the following diagnosis: ' * subarachnoid hemorrhage * active intravascular clotting * severe pulmonary disease (fev \<50% normal) * plasma creatinine \> 115 μmol/l in males, \> 100 μmol/l in females, or hepatic failure) * (renal impairment serum creatinine \> 1.5 times the upper limit of normal nyu) * preoperative anemia \[hemoglobin (hb) \< 11g/dl in females, hb \< 12 g/dl in males\] 9. patients who refuse blood products 10. patients undergoing hormone replacement therapy 11. patients with diagnosed or self-reported cognitive dysfunction; 12. patients who are unable to understand or follow instructions; 13. patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease; 14. patients with bmi over 50 15. any patient that the investigators feel cannot comply with all study related procedures.
c-reactive protein levels among individuals with covid-19

Conditions: Coronavirus Infection

Summary: the primary objective of this multi-center study is to clarify the value of a crp measurement for triage of patients initially presenting with light symptoms of the covid-19 infection. current recommendations of management of covid-19 include large-scale tests for virus. such tests reveal whether an individual is infected with the virus, however, the demonstration of virus per se has no prognostic value for the ensuing course of the covid-19 disease. publications of possible treatments strategies increase exponentially, while evidence of triage of the affected individuals is mainly based on the level of pulmonary affection as measured by the oxygen saturation. to inform decision making for which patients are to be hospitalized due to risk of developing more severe affection, this study addresses the question, whether triage may be performed with the aid of a simple crp measurement.


Eligibility criteria:
inclusion criteria: 1. a test for covid-19 taken at the check point 2. signed, informed consent for blood test to be drawn for the biobank exclusion criteria: 1. former admission to hospital for covid-19 2. direct admission from check point.
several studys showed that upper limb amputated patients are able to experience the illusion of the rubber hand whith prosthesis: we want to go futher by comparing the strength of the incorporation according to the type of prosthesis using the illusion of the rubber hand with prothesis

Conditions: Appropriate Affect

Summary: the goal of this observational study is to compare the strength of the incorporation according to the type of prosthesis (aesthetic, mechanical, myoelectric) with the experience the illusion of the rubber hand. the investigators will replace is the rubber by the patient's prothesis. the population will be people with upper arm amputation above the hand and they will be their own comparation. participants will do the the experience the illusion of the rubber hand in asynchronic and synchronic way and to answer questionnaries.


Eligibility criteria:
inclusion criteria: * at least one upper limb amputation * informed and consented to participate to the study exclusion criteria: * having a history of severe neurological, visual or musculoskeletal impairments (other than the loss of a limb) * with severe serious psychiatric disorders (e.g. schizophrenia) * having problems understanding french in order to guarantee a good understanding of the questionnaires * under guardianship or curatorship
the effects of luo-bu-fu-ke-bi-ri pill

Conditions: Climacteric Syndrome

Summary: to investigate the effect of lbfkbrp on climacteric syndrome in women and explore its therapeutic mechanism.


Eligibility criteria:
clinical diagnosis of climacteric syndrome
an efficacy and safety study of escitalopram long-term treatment in major depressive disorder with associated anxiety symptoms

Conditions: Depressive Disorder, Major

Summary: the purpose of this study is to evaluate the efficacy and safety of long term escitalopram treatment in participants with major depressive disorder (mdd) with associated anxiety symptoms.

this is an open-label (all people know the identity of the intervention), single arm, prospective (study following participants forward in time), post-marketing, multi-center (when more than one hospital or medical school team work on a medical research study) study to evaluate the efficacy and safety of escitalopram in participants with mdd with associated anxiety symptoms. the duration of the study will be 24 weeks at a starting dose of escitalopram 10 milligram per day (mg/day). the dose will be flexibly adjusted (maximum 20 mg/day) after 2 weeks of treatment depending on investigator's discretion. the study will consist of 9 visits: baseline, week 1, 2, 4, 8, 12, 16, 20 and 24. assessments of efficacy and safety will be performed at each visit. the primary efficacy evaluation will be done by montgomery-asbery depression rating scale (madrs) and hamilton anxiety scale(ham-a). participant's safety will also be monitored throughout the study.

Eligibility criteria:
inclusion criteria: * participant must be willing and able to give written informed consent * participant currently suffering from major depressive disorder (mdd) with anxious symptoms including participant with first mdd episode, and relapsed participant with new episode * participant with minimum score at baseline of 22 on the montgomery-asbery depression rating scale (madrs) and minimum score at baseline of 14 on hamilton anxiety rating (ham-a) scales * female participant must be surgically sterile, or practicing an effective method of birth control before entry and throughout the study exclusion criteria: participant who has continuously taken psychoactive substances, antidepressants, anxiolytics, monoamine oxidase inhibitors (maois), psychoactive herbal remedies, lithium, electroconvulsive therapy (ect) carbamazepine in the past 2 weeks before the baseline visit - participants with mdd, requiring treatment systematically within past 2 months from baseline - participants who has contraindication to escitalopram - participant has primary or comorbid diagnoses of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations \[imagining things\], and withdrawal into the self), schizoaffective disorder (a mixed psychiatric disorder relating to a complex psychotic state that has features of both schizophrenia and a mood disorder such as bipolar disorder), bipolar disorder, or dementia (mental decline) - participant who has a significant risk of suicide on clinical assessment or has made a serious suicide attempt within the past 6-month

Keywords: depressive disorder, major escitalopram lexapro
hypnosis to reduce pain and drugs for shoulder dislocation management

Conditions: Shoulder Dislocation

Summary: the effectiveness of hypnosis for reducing pain was evaluated in various medical specialities. however, only few studies have demonstrated the efficacy of hypnosis for the management of pain in the emergency medicine. anteromedial dislocation is a very common reason for admission in emergency department. many methods for reduction have been described but there is no consensus on the optimum technique or sedation procedures. some pain medication and tranquilizers used during a shoulder dislocation management include hemodynamic, respiratory and behavioral adverse effects with the requirement of strengthened surveillance. hypnosis could provide to reduce sedative and analgesic use during the reduction of anteromedial dislocation. the main objective of this study is to evaluate the efficacy of a hypnosis session for reducing the consumption of analgesic in patient throughout a reduction of shoulder dislocation. the investigators also examine the effect of hypnosis on hemodynamic parameters, patient's pain, patient and practitioner satisfaction, sedative consumption, number of attempts for reduction and length of stay in the emergency department.


Eligibility criteria:
inclusion criteria: * patients aged 18 years and over, * checked into ed for an anterior shoulder dislocation suspected by clinical examination and confirmed by radiography, * had given oral consent to participate in the study * are affiliated or be a recipient of a social security plan. * a staff member (nurse, nurse's aide, or physician) trained in hypnosis is available at the patient admission time. exclusion criteria: * patient showing up with a shoulder fracture on x-ray. * patient presenting a shoulder prosthesis. * patient with recurrent dislocations. * patient who does not speak or understand french language. * patient with cognitive dysfunction. * patient with a psychiatric history of psychosis. * patient who is deaf or hard of hearing. * patient under legal protection (guardianship, curatorship). * pregnant women * patient who already benefited of a pre-hospital reduction

Keywords: hypnosis
carvedilol with chemotherapy in second line glioblastoma and response of circulating tumor cells

Conditions: Glioblastoma Multiforme; Glioblastoma

Summary: subjects will receive standard chemotherapy and tumor treated fields (ttfields) and will also receive carvedilol for 4 cycles of treatment. carvedilol will start at 6.25 mg orally twice a day and be increased to 12.5 mg orally twice daily after 1 to 2 weeks if tolerated. peripheral glioma circulating tumor cells (ctc) and brain mri with and without contrast will be obtained at baseline, 2 cycles, and 4 cycles to determine the efficacy and direction of change of the ctc using a new assay tool. preliminary assessment of the tolerability of carvedilol with standard chemotherapy will also be evaluated.

this will be a feasibility study to assess the use of a new pcr assay with response to standard chemotherapy treatment in the second line setting in glioblastoma multiforme (gbm). the change in direction with the combination of carvedilol with standard of chemotherapy based upon brain mri results will be assessed and associating that with also the change in the quantity of tumor cells with a new invented assay device. six subjects will be enrolled in the study who have recurrent gbm and will be receiving second line treatment. the subjects will receive standard therapy per the discretion of the treating oncologist. carvedilol will start at 6.25 mg orally twice daily for 1-2 weeks to confirm tolerance. the subjects will then receive carvedilol at 12.5 mg orally twice daily as the maximum dose and take it continuously for 4 cycles of therapy. at the completion of 4 cycles, patients will stop taking carvedilol. if the patients were on previous anti-hypertensive medications, they will be instructed to restart those medications if stopped on this trial for carvedilol. peripheral blood samples will be collected at baseline before initiation of treatment, on first day of every cycle for four cycles and after the last cycle is completed to obtain peripheral glioma circulating tumor levels. subjects will be re-evaluated for response every 2 cycles of therapy with brain mri with and without contrast.

Eligibility criteria:
inclusion criteria: * grade iv glioblastoma, receiving chemotherapy with or without ttfields. * progressive or recurrent disease requiring second line treatment * evidence of progression of disease by brain mri and are planned to receive chemotherapy exclusion criteria: * current use of another beta blocker that cannot be switched to carvedilol at the onset of the trial. * systolic blood pressure \<90 mmhg and/or heart rate \<60 bpm without hypertensive medications * allergy to beta blockers * severe or uncontrolled asthma or copd (chronic obstructive pulmonary disease)
central sensitization and outcome of endometriosis surgery

Conditions: Endometriosis

Summary: this study will evaluate whether the degree of central sensitization as measured by the questionnaire "central sensitization inventory csi" is related to the outcome of surgical endometriosis treatment


Eligibility criteria:
inclusion criteria: * primary surgery because of pelvic/abdominal pain under suspected diagnosis of and with the aim to confirm endometriosis * elective abdominal surgery in women with pelvic/abdominal pain and confirmed endometriosis exclusion criteria: * patient is unable to give consent * cognitive impairment * patient outcomes questionnaire is not available in a language that the patient knows. * secondary surgery due to complications * endometriosis surgery due to infertility